Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
RESEARCH TOOLSreports
Dianthus Therapeutics (DNTH) Stock Price & Analysis
270 Followers
DNTH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.58 - $33.77
Previous Close$24.01
Volume203.64K
Average Volume (3M)171.39K
Market Cap
$661.18M
Enterprise Value$531.48M
Total Cash (Recent Filing)$173.72M
Total Debt (Recent Filing)$585.00K
Price to Earnings (P/E)-1.8
Beta1.48
Next Earnings
May 09, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.05
Shares Outstanding29,346,760
10 Day Avg. Volume161,848
30 Day Avg. Volume171,387
Standard Deviation0.23
R-Squared0.16
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)3.92
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-21.51
Forecast
1Y Price Target
$41.75Price Target Upside61.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Dianthus Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DNTH FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was $6.58 and its highest was $33.77 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Currently, no data Available
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s upcoming earnings report date is May 09, 2024 which is in 5 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on Mar 21, 2024. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.94 by $0.23.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 29,346,760 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.94. Following the earnings report the stock price went up 14.316%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Among the largest hedge funds holding Dianthus Therapeutics’s share is Fairmount Funds Management Llc. It holds Dianthus Therapeutics’s shares valued at 20M.
---
Dianthus Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.75 (61.82% Upside)
$41.75 (61.82% Upside)
Blogger Sentiment
Bullish
DNTH Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.88%
12-Months-Change
Fundamentals
Return on Equity
-42.05%
Trailing 12-Months
Asset Growth
22.34%
Trailing 12-Months
Company Description
Dianthus Therapeutics
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.
---
DNTH Stock 12 Months Forecast
Average Price Target
$41.75
▲(61.82% Upside)
Technical Analysis
Crinetics Pharmaceuticals
―
Adverum Biotechnologies
―
Fate Therapeutics
―
Minerva Neurosciences
―
Best Analysts Covering DNTH
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
+31.63%
reiterated a buy rating last month
Copying Laura Chico's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +31.63% per trade.
---